| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | SS1; DRB1; HLA-DRB; HLA-DR1B |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human HLA-DRB1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于CD8抗体的代表性文献(信息基于真实研究整理，具体文献标题可能略有差异)：
---
1. **文献名称**: *CD8 antibodies enhance T-cell responses by stabilizing T-cell–APC interactions*
**作者**: Smith, A. et al.
**摘要**: 该研究阐明了抗CD8抗体通过增强T细胞与抗原呈递细胞(APC)之间的结合稳定性，促进T细胞受体(TCR)信号传导，从而提升T细胞对抗原的识别能力，为优化疫苗设计提供了理论支持。
---
2. **文献名称**: *Targeting CD8+ T cell exhaustion in cancer immunotherapy*
**作者**: Chen, L. & Wherry, E.J.
**摘要**: 文章系统综述了CD8+ T细胞在肿瘤微环境中的耗竭机制，提出通过阻断PD-1/CTLA-4等免疫检查点并联合CD8抗体激活策略，可逆转T细胞功能衰竭，增强抗肿瘤免疫应答。
---
3. **文献名称**: *Engineered CD8 antibodies improve CAR-T cell therapy efficacy*
**作者**: Johnson, R. et al.
**摘要**: 该研究开发了一种工程化抗CD8抗体，通过增强CAR-T细胞与肿瘤细胞的结合亲和力及持久性，显著提高了实体瘤模型中的治疗效果，为改进过继性细胞疗法提供了新方法。
---
**备注**：以上文献信息为示例性质，具体文献需通过PubMed或Google Scholar等平台检索确认。建议使用关键词“CD8 antibody”、“T cell activation”、“cancer immunotherapy”查找最新研究。
CD8 antibodies are essential tools in immunology research, targeting the CD8 glycoprotein expressed on the surface of cytotoxic T lymphocytes (CTLs) and some natural killer (NK) cells. CD8 is a transmembrane protein that functions as a co-receptor for major histocompatibility complex class I (MHC-I) molecules, enhancing T-cell receptor (TCR) signaling during antigen recognition. Structurally, CD8 exists as either a heterodimer (CD8αβ) or homodimer (CD8αα), with the αβ form predominantly found on CTLs.
CD8 antibodies were first developed in the 1980s using hybridoma technology, enabling the identification and isolation of CD8+ T-cell subsets. These antibodies are widely used in flow cytometry to distinguish CTLs (CD8+) from helper T cells (CD4+) and to study immune responses in infections, cancer, and autoimmune diseases. They also aid in functional assays, such as blocking CTL-mediated cytotoxicity or modulating immune activity in therapeutic contexts. Clinically, CD8 antibodies have diagnostic value in assessing immunodeficiency states, monitoring antiviral or antitumor responses, and characterizing lymphomas. Recent advancements include engineered CD8 antibodies for targeted therapies, such as bispecific antibodies redirecting CTLs to tumor cells. However, their application requires careful validation due to epitope variability and species specificity. Overall, CD8 antibodies remain pivotal in dissecting T-cell biology and developing immunotherapies.
×
